Immuneering Corporation (IMRX) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Immuneering Corporation (IMRX) closed at USD 3.42 on 2026-10-14, a change of -47.3 % over the past year, with a market capitalization of USD 235.5M.
Immuneering Corporation recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 3.42 |
| 2026-10-13 | 3.56 |
| 2026-10-12 | 3.86 |
| 2026-10-09 | 3.94 |
| 2026-10-08 | 3.74 |
| 2026-10-07 | 3.86 |
| 2026-10-06 | 3.83 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Immuneering Corporation key figures
- Previous close
- USD 3.42 (2026-10-14)
- 1-year change
- -47.3 %
- Market cap
- USD 235.5M
- Enterprise value
- USD 89.23M
- P/E ratio (trailing)
- -3.83
- P/E ratio (forward)
- -2.90
- EPS (trailing)
- -0.95
- EPS (forward)
- -1.26
- PEG ratio
- n/a
- Price to book
- 1.23
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 22.22
- Employees
- 57
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Immuneering Corporation
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Immuneering Corporation and compare it with other stocks.
Analyze IMRXAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Immuneering Corporation shares.